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Temporal inference from laboratory testing results and their triangulation with 
clinical outcomes as described in the associated unstructured text from the providers’ 
notes in the Electronic Health Record (EHR) is integral to advancing precision medicine. 
Here, we studied 181 COVIDpos and 7,775 COVIDneg patients subjected to 1.3 million 
laboratory tests across 194 assays during a two-month observation period centered 
around their SARS-CoV-2 PCR testing dates. We found that compared to COVIDneg at the 
time of clinical presentation and diagnostic testing, COVIDpos patients tended to have 
higher plasma fibrinogen levels and similarly low platelet counts, with approximately 25% 
of patients in both cohorts showing outright thrombocytopenia. However, these measures 
show opposite longitudinal trends as the infection evolves, with declining fibrinogen and 
increasing platelet counts to levels that are lower and higher compared to the COVIDneg 
cohort, respectively. Our EHR augmented curation efforts suggest a minority of patients 
develop thromboembolic events after the PCR testing date, including rare cases with 
disseminated intravascular coagulopathy (DIC), with most patients lacking the platelet 
reductions typically observed in consumptive coagulopathies. These temporal trends 
present, for the first time, fine-grained resolution of COVID-19 associated coagulopathy 
(CAC), via a digital framework that synthesizes longitudinal lab measurements with 
structured medication data and neural network-powered extraction of outcomes from the 
unstructured EHR. This study demonstrates how a precision medicine platform can help 
contextualize each patient’s specific coagulation profile over time, towards the goal of 
informing better personalization of thromboprophylaxis regimen. 
 
Introduction 
There is a growing body of evidence that severe COVID-19 outcomes may be associated 
with dysregulated coagulation1, including stroke, pulmonary embolism, myocardial infarction, and 
other venous or arterial thromboembolic complications2. This so-called COVID-19 associated 
coagulopathy (CAC) shares similarities with disseminated intravascular coagulation (DIC) and 
thrombotic microangiopathy but also has distinctive features3. Given the significance of CAC to 
COVID-19 mortality, there is an urgent need for fine-grained resolution into the temporal 
manifestation of CAC, particularly in comparison to the broad-spectrum of other, better 
characterized coagulopathies. While there is a growing body of evidence suggesting associations 
between COVID-19 infection and mortality with thrombocytopenia, D-dimer levels, and 
prolongation of prothrombin time, the potentially heterogeneous signatures of CAC onset and 
progression as well as their connection to clinical outcomes are not well defined 1,4,5. An advanced 
understanding of this phenotype may aid in risk stratifying patients, thus facilitating optimal 
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monitoring strategies during disease evolution through the paradigm of precision medicine, which 
hopefully will lead to further improvements in treatment decisions and overall survival.  
To this end, we instituted a holistic data science platform across an academic health care 
system that enables machine intelligence to augment the curation of phenotypes and outcomes 
from 15.2 million EHR clinical notes and associated 3 million lab tests from 1,192 COVID-19-
positive (COVIDpos) and 47,344 confirmed COVID-19-negative (COVIDneg) patients over a 
retrospectively defined 2-month observation period straddling the date of the PCR test (see 
Methods). By compiling all available laboratory testing data for the 30 days preceding the SARS-
CoV-2 PCR diagnostic testing date (‘day 0’), as well as the 30 days following the diagnostic testing 
date, and triangulating this information with medications and clinical outcomes, we were able to 
identify laboratory abnormalities significantly associated with positive COVID-19 diagnosis. We 
identified coagulation-related parameters among this set of abnormalities and then studied 
aggregate as well as individual patient trajectories that could aid in extracting a temporal signature 
of CAC onset and progression. We also correlated these signals with the clinical outcomes of 
these patients.  
In order to hone into longitudinal lab test trends that would apply at the individual patient 
level, we restricted our analysis to patients with available serial testing data, which had at least 3 
test results of the same type during the observation period.  After applying these inclusion criteria, 
181 COVIDpos and 7,775 COVIDneg patients met study inclusion criteria. The median age in the 
COVIDpos and COVIDneg groups were 59.9 years and 63.9 years respectively (see Methods and 
Table 1), and the numbers of males were 96 (53%) and 4,064 (52%), respectively. The number 
of pre-existing coagulopathies in the COVIDpos and COVIDneg groups were 56 (33%) and 3,325 
(40%), respectively.  Overall, more patients in the COVIDneg cohort were hospitalized at the start 
of the study period.  In particular, the number of COVIDpos patients hospitalized on the SARS-
CoV-2 PCR testing date was 23 (12.7%), compared to 1435 (18.5%) for the COVIDneg cohort. In 
order to balance some of these clinical covariates and others between the two cohorts, we applied 
1:10 propensity score matching to define a subset of 1,810 patients from the COVIDneg cohort to 
use for the final statistical analyses (see Methods).  In particular, the general categories of 
covariates considered for balancing included: demographics, anticoagulant/antiplatelet 
medication use, and hospital admission status.  Population-level characteristics of the COVIDpos, 
COVIDneg, and the final propensity score-matched COVIDneg cohorts are summarized in Table 1.   
  
Results 
Longitudinal analysis highlights classes of lab abnormalities in COVID-19 progression 
 To identify laboratory test results which differ between COVIDpos and COVIDneg patients, 
we analyzed longitudinal trends for 194 laboratory test results in the 30 days prior to and after the 
day of PCR testing (designated as day 0). As most patients did not undergo laboratory testing for 
each assay on a daily basis, we grouped the measurements into time windows reflecting potential 
stages of infection as follows: pre-infection (days -30 to -11), pre-PCR (days -10 to -2), time of 
clinical presentation (days -1 to 0), and post-PCR phases 1 (days 1 to 3), 2 (days 4-6), 3 (days 7-
9), 4 (days 10-12), 5 (days 13-15), and 6 (days 16-30). We only considered test-time window pairs 
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in which there were at least three patients contributing laboratory test results in both groups. 
During each time window, we then compared the distribution of results from COVIDpos versus 
COVIDneg patients, allowing us to identify any lab tests which were significantly altered in 
COVIDpos patients during any time of disease acquisition, onset, and/or progression.  
 Out of 863 lab test-time window pairs with adequate data points for comparison, we 
identified 88 such pairs (comprising 36 unique lab tests) which met our thresholds for statistical 
significance (Cohen’s D > 0.35, BH-adjusted Mann-Whitney p-value < 0.05) (Table 2). Among 
these were lab tests which may be considered positive controls for our analysis, including a 
reduction in blood oxygenation in COVIDpos patients after diagnosis and elevated titers of SARS-
CoV-2 IgG antibodies in the late phase 6 (days 16-30) after diagnosis (Figures 1A-B). We also 
identified abnormalities in several other classes of lab tests, including immune cell counts 
(Figures 1C-G), erythrocyte-related tests (Figures 1H-I), serum chemistry (Figures 1J-K), and 
coagulation-related tests (Figure 2).  
With respect to coagulation, we found that plasma fibrinogen was significantly elevated in 
COVIDpos patients at the time of diagnosis (Cohen’s D = 1.092, BH-adjusted Mann-Whitney p-
value = 0.016, Table 2, Figure 2A). This hyperfibrinogenemia generally resolved during the 10 
days following diagnosis, even declining to levels significantly lower than the COVIDneg cohort 
(Figure 2A). Conversely, platelet counts were lower in the COVIDpos cohort at the time of clinical 
presentation but tended to increase over the subsequent 10 days to levels significantly higher 
than those in COVIDneg patients (Cohen’s D = 0.361, BH-adjusted Mann-Whitney p-value = 0.008, 
Table 2, Figure 2B). While thrombocytopenia has been reported in COVID-19 patients before6,7, 
an upward trend in platelet counts after diagnosis has not been described to our knowledge. 
Among other coagulation-related tests, we found no difference in prothrombin time (PT) and slight 
elevations in activated partial thromboplastin times (aPTT) after diagnosis (Figure 2C). D-dimer 
levels were frequently above normal limits in both the COVIDpos and COVIDneg cohorts and were 
not significantly different between these cohorts during any time windows (Figure 2D). Of note, 
the observed trends in both fibrinogen and platelet counts could not be attributed to the 
administration of either antiplatelet or anticoagulant therapies, as drug class-matched cohorts of 
COVIDneg patients failed to show these trends after the day of PCR testing (Figures 2E-F). 
We also performed similar analyses comparing the COVIDpos and COVIDneg cohorts using 
different time windows definitions including daily trends (Figure 3). This approach offers the 
advantage of increased granularity at the cost of sample size per time point, but we did identify 
similar lab tests as altered in COVIDpos patients using each approach including the fibrinogen 
decline and platelet increase in the COVIDpos cohort after diagnosis (Figure 3). 
 
Thrombosis is an enriched phenotype among COVID19 patients undergoing longitudinal 
lab testing 
 Given the recently described coagulopathies associated with COVID-191,2,3, we were 
intrigued by these temporal trends in fibrinogen levels and platelet counts in the COVIDpos cohort. 
We next asked whether the observed coagulation-related laboratory trends were associated with 
clinical manifestations of thrombosis. To do so, we employed a BERT-based neural network8 (see 
Methods) to identify patients who experienced a thrombotic event after their SARS-CoV-2 testing 
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date. Specifically, we extracted diagnostic sentiment from EHR notes (e.g. whether a patient was 
diagnosed with a phenotype, suspected of having a phenotype, ruled out for having a phenotype, 
or other) regarding specific thromboembolic phenotypes including pulmonary embolism (PE), 
deep vein thrombosis (DVT), venous thromboembolism (VTE), thrombotic stroke, myocardial 
infarction, and cerebral venous thrombosis.  
We found that 40 of the total 1729 COVIDpos cohort (2.3%) were positively diagnosed with 
one or more of these phenotypes in the 30 days after PCR testing, with the majority of these 
patients (27 of 40; 68%) experiencing a DVT. Interestingly, we found that after creating subsets 
of the patients with longitudinal lab testing data (i.e. the patients meeting the criteria for inclusion 
in our study), 33 of the 181 patients (18%) had at least one EHR-derived clot diagnosis, including 
25 patients with DVT (Table 6). Thus, the cohort under consideration here is highly enriched 
(Table 4; hypergeometric p-value < 1x10-20) for patients experiencing thrombotic events 
compared to the overall COVIDpos cohort.  
Longitudinal platelet trends are not strongly associated with the development of 
thrombosis in COVID-19 patients 
 Among the 181 COVIDpos patients with longitudinal lab testing data, only 10 were serially 
tested starting at clinical presentation for fibrinogen versus 87 tested for platelets. As such, we 
first analyzed whether associations exist between platelet counts (or temporal alterations thereof) 
and clotting propensity in this cohort. Among these 87, there were 68 patients without thrombosis 
after PCR-based diagnosis (“non-thrombotic”) and 19 patients with thrombosis (“thrombotic”). 
Thrombocytopenia (platelet count <150x109/L) was observed in ~25% of COVIDpos (and 
COVIDneg) patients at the time of diagnosis (Figure 4A), but the platelet levels at this time point 
were not associated with the subsequent formation of a blood clot in the COVIDpos cohort (Figure 
4B).  
We hypothesized that the previously discussed increase in platelet counts after COVID-
19 diagnosis may be associated with the development of blood clots. If true, then we would expect 
the thrombotic COVIDpos cohort to show significantly higher maximum platelet counts during their 
course of disease progression compared to the non-thrombotic COVIDpos cohort. We found that 
this was not the case, as maximum platelet counts were similar in the two groups (Figure 4C). 
Similarly, among the 74 COVIDpos patients with at least one post-diagnosis platelet count higher 
than that at the time of presentation, the degree of maximal platelet increase was not associated 
with the development of thrombosis (Figure 4D). It would certainly be of interest to perform this 
same analysis on the larger COVIDpos cohort (n = 1729; 40 thrombotic vs. 1689 non-thrombotic), 
but we were not able to do so given the lack of longitudinal testing available for the large majority 
of non-thrombotic COVIDpos patients (Table 3).  
Conversely, we explored whether some COVIDpos patients may experience clotting in the 
setting of low or declining platelets (e.g., consumptive coagulopathy) despite the population-level 
trend of increasing platelets over time. Indeed, we found that 4 of 19 thrombotic patients showed 
absolute platelet counts below 100x109/L during at least one post-diagnosis time window (below 
dotted red line in Figure 4E). We next identified all COVIDpos patients who showed at least one 
post-diagnosis platelet count lower than the count at the time of diagnosis. Interestingly, the binary 
presence of post-diagnosis platelet reductions was associated with thrombotic status (n = 27 of 
5 
68 in non-thrombotic population; n = 14 of 19 in thrombotic population; p = 0.0017). While the 
maximum degree of absolute platelet reduction was not associated with clot development overall 
(p = 0.15; Figure 4F), we did find that 3 of the 15 thrombotic patients experienced a reduction of 
at least 100x109/L relative to the time of diagnosis (below gray line in Figure 4F). Of note, similar 
fractions of non-thrombotic COVIDpos patients also showed these low or declining platelet counts, 
indicating that these trends are not specific indicators of thrombosis (Figures 4E-F).   
Consumptive coagulopathy contributes to a small fraction of COVID-19 associated 
thromboses  
 The observed declining platelet counts and thrombocytopenia in the context of thrombosis 
in a small fraction of COVIDpos patients is consistent with previous reports that fewer than 1% of 
survivors, but over 70% of non-survivors, meet the International Society on Thrombosis and 
Hemostasis (ISTH) criteria for disseminated intravascular coagulation (DIC)1. As was previously 
noted, hyperfibrinogenemia was among the strongest lab test features distinguishing COVIDpos 
from COVIDneg patients at diagnosis, but the subsequent downward trend (Figure 2B) could be 
attributed to a resolving acute phase response and/or consumption of fibrinogen in a systemic 
coagulopathy. Using our BERT-based sentiment extraction, we found that only 2 of the 1729 
COVIDpos patients were diagnosed with DIC, all of whom were included in our longitudinal cohort 
of 181 COVIDpos patients. Both extracted diagnoses were manually confirmed by EHR review. 
This finding suggests that declining fibrinogen after COVID-19 diagnosis typically represents a 
physiologic return to normal range rather than pathologic coagulation factor consumption. To 
further examine the plasma fibrinogen trends among COVID-19 patients with DIC, with non-DIC 
thrombosis, and without thrombosis, we examined patient-level lab test trends from the 10 
individuals who were tested for fibrinogen both at the time of diagnosis and at least two times 
subsequently.  
 This patient-level analysis indeed revealed multiple distinct trajectories with respect to 
fibrinogen and other coagulation parameters in COVIDpos patients. Four of these ten individuals 
developed at least one blood clot during their hospital course. Only one was identified by our 
BERT model (and confirmed by manual EHR review) to have low-grade DIC, and as expected we 
found this patient’s longitudinal lab test pattern to be consistent with consumptive coagulopathy 
(Patient 124; Figure 5A). At the time of diagnosis, this patient showed significant 
hyperfibrinogenemia with elevated D-dimers (1304.5 ng/mL) and a borderline normal platelet 
count (153x109/L). Over the next ten days, this patient’s fibrinogen levels consistently decreased, 
reaching a minimum of 110 mg/dL on day 9. Similarly, after an initial recovery to 190x109/L the 
platelet counts consistently declined starting on day 2 post-diagnosis, reaching a minimum of 
117x109/L on day 11. D-dimer levels exponentially increased after 5 days, reaching a maximum 
of 41,300 ng/mL on day 10. Phenotypically, this patient experienced both thrombotic (right internal 
jugular vein and right superior thyroid artery) and hemorrhagic (oropharyngeal and pulmonary) 
events. This combination of lab results and clinical manifestations is consistent with the diagnosis 
of DIC-like consumptive coagulopathy during the first week after COVID-19 diagnosis.  
 Lab test results from the other three non-DIC thrombotic patients with longitudinal 
fibrinogen testing confirm the presence of alternative forms of coagulopathy in the COVID-19 
population. Patient 23 developed a clot on day 4 post-diagnosis in the context of a declining 
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fibrinogen level and increasing D-dimers but steady platelet counts, which actually increased 
shortly thereafter (Figure 5B). Patient 79 developed several clots after day 3 post-diagnosis in 
the setting of upward trending platelets (which eventually exceed the upper limit of normal) and 
elevated levels of both fibrinogen and D-dimers (Figure 5C). Patient 94 developed a clot on day 
8 post-diagnosis with relatively stable platelet counts within normal limits and steadily declining 
fibrinogen levels (Figure 5D).  
Whether early elevations in plasma fibrinogen contribute to the clotting observed in the 
non-DIC like COVIDpos cohort is unfortunately not possible for us to assess here as only one of 
the ten patients who received fibrinogen testing at the time of clinical presentation and twice 
subsequently developed thrombosis, and this patient was diagnosed with DIC. This hypothesis 
may warrant further analysis in cohorts with more longitudinal fibrinogen data, but again it is 
important to note that several COVIDpos patients who presented with hyperfibrinogenemia did not 
go on to develop thromboses (Figures 5E-F). This emphasizes that a steady post-diagnosis 
decline in plasma fibrinogen may represent physiologic resolution of acute phase response rather 
than a pathologic consumption of fibrinogen and other coagulation factors (Figures 5B, D-F).  
Taken together, this analysis affirms that a DIC-like coagulopathy resulting in a 
combination of hemorrhage and thrombosis can develop in the setting of COVID-19 infection. 
However, the observations that (1) DIC was formally diagnosed in only 2 of 1729 COVIDpos 
patients and (2) 32 of 54 thrombotic COVIDpos patients with serial platelet testing never showed a 
single platelet count lower than that obtained on day 0 emphasizes that consumptive 
coagulopathy is an exception rather than the rule as it pertains to thrombotic phenotypes in 
COVID-19 patients.  
 
Discussion 
 A number of studies on clinical characteristics and lab tests are shedding light on the 
spectrum of hematological parameters associated with COVID-19 patients. In an initial study of 
41 patients from Wuhan, the blood counts in COVIDpos patients showed leukopenia and 
lymphopenia, and prothrombin time and D-dimer levels were higher in ICU patients than in non-
ICU patients9. Another study based on 343 Wuhan COVIDpos patients found that a D-dimer level 
of at least 2.0 µg/ml could predict mortality with a sensitivity of 92.3% and a specificity of 83.3%10. 
An independent study of 43 COVID-19 patients found significant differences between mild and 
severe cases in plasma interleukin-6 (IL-6), D-dimers, glucose, thrombin time, fibrinogen, and C-
reactive protein (P <0 .05)4. While such studies indeed highlight that hematological and 
inflammatory abnormalities are prevalent in COVIDpos, a high-resolution temporal understanding 
of how these parameters evolve in COVID-19 patients post diagnosis has not been established. 
Specifically, in the wake of accumulating evidence for hypercoagulability in COVIDpos patients, 
there are important clinical questions emerging regarding the necessity of and guidelines for 
thromboprophylaxis in patient management.  
 The ability to derive this longitudinal understanding of COVID-19 progression, including 
laboratory abnormalities and their associated clinical manifestations, mandates the synthesis of 
structured and unstructured EHR data (e.g., lab tests and clinical notes) at a large scale. The fact 
that tens of thousands of patients have undergone SARS-CoV-2 testing at major academic 
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medical centers (AMCs) provides an abundance of potential data to perform this analysis but also 
poses significant challenges from a practicality standpoint. Manual review and curation of patient 
trajectories and associated testing results is not practical, nor is it likely to provide comprehensive 
or even entirely accurate individual patient records. Rather, triangulation across datasets, 
including lab measurements, clinical notes, and prescription information, using a scalable digitized 
approach to extract structured data along with sentiment-surrounded clinical phenotypes and 
outcomes is required to efficiently perform this analysis in a timely fashion.  
 By developing and deploying such a digitized platform on the entirety of EHR data from a 
large AMC, we have identified in an unbiased manner, laboratory abnormalities that characterize 
COVIDpos patients from their COVIDneg counterparts who also presented with symptoms leading 
to the performance of a SARS-CoV-2 PCR test. The abnormalities in coagulation-related tests, 
including fibrinogen and platelets, were intriguing in the context of literature reporting the 
occurrence of various clotting phenotypes in COVID-19 patients, including DIC-like consumptive 
coagulopathies along with more isolated clotting events in the lungs, central nervous system, and 
other tissues1,2,3. Our finding that consumptive coagulopathy represents a minority of COVID-19 
associated clotting events corroborates and provides context for other studies which have 
reported overt DIC or DIC-like disease in over 70% of non-survivors but far lower fractions of 
survivors1. A study of 83 COVID-19 patients suggests that when LMWH prophylaxis was initiated 
on hospital admission, progression to DIC was rare11. 
 While our analysis highlights that consumptive coagulopathy should be considered in the 
minority of COVIDpos patients with significant serial reductions in platelet counts, it remains to be 
seen whether the post-diagnosis platelet increases or early hyperfibrinogenemia which we 
observed may contribute mechanistically to the clotting in the much larger non-DIC thrombotic 
COVID-19 population. It is important to note that despite the trend of increasing platelets, the 
platelet count only extended above the normal range (>450x109/L) in 24 of 135 COVIDpos patients 
with serial measurements, and the development of such outright thrombocytosis was observed 
with similar frequencies in the thrombotic and non-thrombotic cohorts. Further, the fact that 
several patients with elevated fibrinogen (i.e. >400 mg/dL) at presentation did not develop 
thromboses suggests that early hyperfibrinogenemia is not a singular driver of subsequent clotting 
events, but a small sample size (n = 10 patients; 9 non-thrombotic vs. 1 thrombotic) limited the 
power of this analysis.  
 Despite these uncertainties, this linking of longitudinal trends to patient outcomes provides 
several useful pieces of clinical information, including but not limited to: (1) Early 
hyperfibrinogenemia is to be expected in COVID-19 patients and may not be useful in determining 
an appropriate thromboprophylaxis approach for a given patient. (2) Declining fibrinogen levels 
shortly after diagnosis are also expected and likely represent the resolution of an acute phase 
response in most patients rather than a decline secondary to the onset of consumptive 
coagulation. (3) Borderline or overt thrombocytopenia is common in COVID-19 patients at the 
time of clinical presentation, and the initial platelet count does not robustly predict patients who 
are likely to develop thromboses. (4) After diagnosis, COVID-19 patients generally show an 
upward trend in platelets. Patients whose platelets trend down after diagnosis should be 
monitored, as platelet reductions after clinical presentation are associated with thromboses and 
significant reductions may be indicative of ongoing consumptive coagulopathy.  
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 There certainly remains much to understand regarding the molecular pathophysiology 
underlying COVID-19 associated thrombosis. While elevations in fibrinogen and D-dimer have 
been reported (and confirmed by our analyses), the circulating levels of tissue factor and other 
coagulation factors have not been assessed broadly in this population. Interestingly, single cell 
RNA-sequencing data highlights that the respiratory tract, including the nasal cavity, are strongly 
enriched for high expression of tissue factor (encoded by the gene F3) (Figure 6A). Specifically, 
F3 is highly expressed in epithelial cells of these tissues - the same cell types which have been 
found to express ACE2, the putative entry receptor for SARS-CoV-2 (Figures 6B-C). Type II 
pneumocytes, which may also express ACE2 and have been reported as a putative entry site for 
SARS-CoV-212–14, are also strongly enriched among all human cell types showing high F3 
expression (Figure 6A). Whether infection-related damage to these epithelial cells may lead to 
shedding of tissue factor into circulation or its increased exposure circulating coagulation factors 
locally in respiratory tissues would be interesting to evaluate. Such a mechanism could at least 
partially contribute to the development of clots systemically and locally in the pulmonary 
vasculature. This has been confirmed in at least 3 autopsy series that reported both microthrombi 
and pulmonary emboli in a significant proportion of COVID-19 patients15. 
 In addition to our findings regarding abnormal coagulation parameters in COVID-19 
patients, we identified several other laboratory features which differed from the COVIDneg cohort. 
For example, others have previously reported leukopenia and T cell deficiencies in COVID-19 
patients at presentation 9,16; we identified a leukopenia which existed both prior to and at the time 
of clinical presentation which recovered during the week following COVID-19 diagnosis (Figure 
1C). Specifically, we found that monocytes, basophils, neutrophils, and eosinophils followed this 
temporal trend (Figures 1D-G). With respect to erythrocytes, we found that both COVIDpos and 
COVIDneg patients developed a worsening mild anemia after PCR testing, but the trajectory was 
actually slower for COVIDpos patients (Figures 1B, 1H, Table 1). This progressive anemia was 
interestingly paralleled by a declining mean corpuscular volume unique to the COVIDpos cohort 
(Figure 1I). This may represent an inflammation associated anemia and could simply be related 
to repeated blood testing (i.e., mild blood loss) in these patients. Among serum chemistry tests, 
we observed distinct patterns showing reduced calcium in COVIDpos patients at presentation and 
through the first week of infection versus elevated magnesium between days 4 and 15 (Figures 
1J-K). While low calcium at the time of presentation has been previously described in COVID-19 
patients 17, elevations in serum magnesium levels in the 1-2 weeks after diagnosis have not been 
reported. Determining whether these serum chemistry alterations are induced by SARS-CoV-2 or 
have any impact on viral replication or pathogenicity, although preliminary analyses have shown 
no association between these lab measurements at any time point and patient mortality (not 
shown).  
It is important to note that while we center the study period around the PCR testing date, 
this date may not correspond to the same disease state of COVID-19 for each individual in the 
COVIDpos cohort. Additionally, there are several covariates which may influence these longitudinal 
trends and should be explored further. For example, we have already considered whether 
previous or concomitant administration of anticoagulants or antiplatelet agents influences patient 
lab test results and/or outcomes. In Figure 2D-E, we present the longitudinal platelet counts and 
fibrinogen levels for subsets of the COVIDpos and COVIDneg cohort who are on and off these 
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medications. While we do observe elevated levels of platelets generally in the COVIDneg cohort 
who are on antiplatelets, this potential medication effect does not alone account for the differences 
in platelet levels that we observe in the COVIDpos cohort. Similarly, the authors wish to explore 
whether longitudinal lab measurement trends differ between outpatient, inpatient, and ICU 
admitted patient cohorts. New data sets can also be utilized; for example, rather than grouping 
patients by the identified thromboembolic phenotypes extracted from the clinical notes alone, 
patients could be stratified by those who had imaging studies (Duplex ultrasound, CT scan, etc.) 
performed, and phenotypes could be directly extracted from these procedural reports. As more 
data accumulates from COVIDpos and COVIDneg patients in the coming months, these analyses 
will be expanded to assess similarities and differences in the temporal trends of laboratory test 
results among a wider range of patient subgroups relevant for COVID-19 outcomes, such as those 
who have pre-existing conditions (e.g., diabetes, hypertension, obesity, malignancies) or patients 
who are on specific medication (e.g., ACE inhibitors, statins, immunosuppressants).  
 In summary, this work demonstrates significant progress in our goal of enabling scaled 
and digitized analyses of longitudinal unstructured and structured EHR records to identify 
variables (e.g., laboratory results) which are associated with relevant clinical phenotypes (e.g., 
COVID-19 diagnosis and outcomes). In doing so, we identified trends in lab test results which 
may be relevant to monitor in COVID-19 patients and warrant both clinical and mechanistic follow-
up in more targeted and explicitly controlled prospective analyses.  
 
Figure Legends 
Figure 1. Longitudinal and temporally resolved analysis highlights positive control lab 
tests elevated in COVIDpos patients along with immune, hematologic, and serum chemistry 
signatures.  (A-K) Longitudinal trends of various lab tests in COVIDpos (red) versus COVIDneg 
(blue) patients. For any windows of time during which at least one patient in each cohort had test 
results, data is shown as mean with standard errors. Values given horizontally along the top of 
the plot are BH-adjusted Mann-Whitney test p-values. Values in red correspond to lab test-time 
point pairs which met the cutoffs for statistical significance (adjusted p-value < 0.05 and Cohen’s 
D > 0.35). Values given horizontally along the bottom of the plot are the numbers of patients in 
the COVIDneg and COVIDpos cohorts, respectively (i.e. “# COVIDneg | # COVIDpos).  
 
Figure 2. COVIDpos patients show distinctly opposite temporal trends in platelet counts and 
fibrinogen starting at the time of diagnosis. (A-B) Longitudinal trends of platelet counts and 
fibrinogen in COVIDpos (red) versus COVIDneg (blue) patients. For any time windows during which 
at least one patient in each cohort had test results, data is shown as mean with standard errors. 
Values given horizontally along the top of the plot are BH-adjusted Mann-Whitney test p-values. 
Values in red correspond to lab test-time point pairs which met the cutoffs for statistical 
significance (adjusted p-value < 0.01 and Cohen’s D > 0.35). Values given horizontally along the 
bottom of the plot are the numbers of patients in the COVIDneg and COVIDpos cohorts, respectively 
(i.e. “# COVIDneg | # COVIDpos). (C) Longitudinal trends of other coagulation-related tests including 
prothrombin time (PT), activated partial thromboplastic time (aPTT), and D-dimers. (D-E) Trends 
in platelet counts and fibrinogen levels at daily resolution with COVIDpos and COVIDneg cohorts 
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stratified based on administration of anticoagulant or antiplatelet agents. For each cohort, average 
lab values and standard errors are shown for each day with at least three observations. 
 
Figure 3. Aggregate results from 9 selected lab tests for COVIDpos and COVIDneg (Matched) 
patient cohorts over a 60-day period centered around the PCR diagnostic testing date (day 
0).  Lab tests include: (A) Platelets; (B) Fibrinogen, Plasma; (C) Prothrombin Time, Plasma; (D) 
Activated Partial Thromboplastin Time; (E) D-Dimer; (F) Magnesium, Serum/Plasma; (G) 
Basophils Absolute; (H) Neutrophils, Blood; (I) Alkaline Phosphatase, Serum.  References ranges 
are shown at the top of each plot.  For each cohort, average lab values and standard errors are 
shown for each day with at least three observations.   
 
Figure 4. Association between platelet counts and thrombosis in COVIDpos and COVIDneg 
cohorts. (A) Distribution of platelet counts at the time of PCR testing for COVIDpos cohort. Vertical 
dotted gray lines correspond to upper and lower limits of normal platelet counts (150-450x109/L). 
(B) Comparison of platelet counts at time of PCR testing between COVIDpos patients who did not 
(red) and did (blue) subsequently develop thromboses. (C) Comparison of maximum platelet 
counts (considering counts at and after clinical presentation for PCR testing) between COVIDpos 
patients who did not and did subsequently develop thromboses. (D) Comparison of maximum 
degree of platelet increase after clinical presentation in COVIDpos patients who did not and did 
subsequently develop thromboses. (E) Comparison of minimum platelet counts (considering 
counts at and after clinical presentation for PCR testing) between COVIDpos patients who did not 
and did subsequently develop thromboses. (F) Comparison of maximum degree of platelet 
decline after clinical presentation in COVIDpos patients who did not and did subsequently develop 
thromboses. 
Figure 5. Longitudinal analyses of platelet counts, plasma fibrinogen, and D-dimer levels 
in individual patients with or without thrombotic disease. (A) Patient 124 developed 
hemorrhagic and thrombotic phenotypes in the context of declining fibrinogen, declining platelets, 
and increasing D-dimers. This is consistent with a DIC-like coagulopathy. (B) Patient 23 
developed clots in the setting of declining fibrinogen and elevated D-dimers but stable platelet 
counts which increased shortly thereafter. (C) Patient 94 developed clots while showing increases 
in platelet counts along with plasma fibrinogen and D-dimers. (D) Patient 94 developed clots with 
relatively stable platelet counts and steadily declining plasma fibrinogen. (E) Patient 13 did not 
develop clots or bleeding despite coordinate decrease in platelet counts and fibrinogen which may 
be mistaken for a DIC-like coagulopathy. (F) Patient 51 did not develop clots despite showing a 
post-diagnosis decline in plasma fibrinogen similar to several patients in the thrombotic cohort.  
Figure 6. Single cell RNA-sequencing highlights expression of tissue factor (factor 3, F3) 
in respiratory epithelial cells which also express ACE2. (A) Across >1.9 million single cell 
samples, cells from the respiratory tract and nasal cavity are strongly enriched for high expression 
of the tissue factor (F3 gene). Further, type II pneumocytes are among the cell types that are most 
strongly enriched for high expression of the tissue factor gene. (B-C) Violin plot representations 
showing expression of tissue factor (B) and ACE2 (C), the putative SARS-CoV-2 entry receptor, 
in epithelial cells from the respiratory tract and nasal cavity. Data is from a previously published 
study by Durante, et al.18 
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Methods 
Study design, setting and patient population 
This is a retrospective study of patients who underwent polymerase chain reaction (PCR) 
testing for suspected SARS-CoV-2 infection at the Mayo Clinic and hospitals affiliated to the Mayo 
health system.  
This research was conducted under IRB 20-003278, “Study of COVID-19 patient 
characteristics with augmented curation of Electronic Health Records (EHR) to inform strategic 
and operational decisions”. All analysis of EHRs was performed in the privacy-preserving 
environment secured and controlled by the Mayo Clinic. Nference, the Mayo Clinic, and the 
Janssen pharmaceutical companies of Johnson & Johnson (J&J) subscribe to the basic ethical 
principles underlying the conduct of research involving human subjects as set forth in the Belmont 
Report and strictly ensure compliance with the Common Rule in the Code of Federal Regulations 
(45 CFR 46) on the Protection of Human Subjects. 
Longitudinal lab testing tied to COVID-19 PCR diagnostic testing 
We analyzed data from 48,536 patients who received PCR tests from the Mayo Clinic 
between February 15, 2020 to May 8, 2020.  Among this population, 1,192 patients had at least 
one positive SARS-CoV-2 PCR test result, and 47,344 patients had all negative PCR test results.  
In order to align the data for the analysis of aggregate longitudinal trends, we selected a reference 
date for each patient.  For patients in the COVIDpos cohort, we used the date of the first positive 
PCR test result as the reference date (day = 0).  For patients with all negative PCR tests, we used 
the date of the first PCR test result as the reference date (day = 0).  We defined the study period 
for each patient to be 30 days before and after the PCR testing date. Patients with contradictory 
PCR test results were excluded for the purpose of this analysis; e.g. a positive PCR test result 
and a negative PCR test result on the same day, or a positive PCR test result followed 
immediately by several negative PCR test results. 
Over 3 million test results from 5,536 different types of lab tests were recorded for the 
patients who received PCR tests in the 60-day windows surrounding their PCR testing dates at 
the Mayo Clinic campuses in Minnesota, Arizona and Florida. Among these lab tests, we 
restricted our analysis to 194 tests with at least 1000 observations total and at least 10 
observations from the COVIDpos cohort.  In addition, we considered different subsets of the 
COVIDpos cohort for the analysis of each of the 194 lab tests, due to differences in availability of 
testing results.  For each lab test, we consider the results from patients with 3 or more 
observations during the study period.   
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In the end, there are 181 COVID-19 positive and 7,775 COVID-19 negative patients that 
had 3 or more test results during the study period for at least one of the assays among the 194 
lab tests considered.  We take this set of 181 COVID-19 positive patients to be the COVIDpos 
cohort.  In order to construct the COVIDneg cohort from the 7,775 COVID-19 negative patients, we 
apply propensity score matching, which is described in the next section.   
Propensity score matching to select the final COVIDneg cohort 
 To construct a COVIDneg cohort similar in baseline clinical covariates to the COVIDpos 
cohort, we employ 1:10 propensity score matching19.  In particular, first we trained a regularized 
logistic regression model to predict the likelihood that each patient will have a positive or negative 
COVID-19 test result, using the following covariates: demographics (age, gender, race), 
anticoagulant/antiplatelet medication use (orders for alteplase, antithrombin III, apixaban, 
argatroban, aspirin, bivalirudin, clopidogrel, dabigatran, dalteparin, enoxaparin, eptifibatide, 
heparin, rivaroxaban, warfarin in the past year and in the past 30 days), and hospitalization status 
(i.e. whether or not the patient was hospitalized on the date of PCR testing). 
Using the predictions from the logistic regression model as propensity scores, we then 
matched each of the 181 patients in the COVIDpos cohort to 10 patients out of the 7,775 COVID-
19 negative patients, using greedy nearest-neighbor matching without replacement20.20  As a 
result, we ended up with a final COVIDneg cohort that included 1,810 patients with similar baseline 
characteristics to the COVIDpos cohort.  The characteristics of the two cohorts are summarized in 
Table S1.   
Further, for the analyses conducted on individual lab tests, which include only a subset of 
patients from the COVIDpos cohort, we use the propensity scores to match each patient from the 
COVIDpos cohort to 10 patients from the COVIDneg cohort which have the most similar propensity 
scores and lab tests available.  For example, for the Fibrinogen lab test, in which we have data 
on 10 patients from the COVIDpos cohort, we select 100 patients from the COVIDneg cohort with 
Fibrinogen lab tests available and the most similar propensity scores to be the control group.  In 
this way, we ensure that all of the comparisons are done between subsets of the positive and 
negative cohorts with similar propensity scores, and therefore similar underlying characteristics.   
Statistical significance assessments over 1-month post SARS-CoV-2 PCR diagnosis date  
To identify tests that show significant differentiation, we first compared the overall 
distributions of test scores of COVIDpos vs COVIDneg over the 30-day period following testing.  
For each test the procedure was to: 
(1) Compute a single score per patient by averaging all their tests over the duration (may be 
1 or many tests per patient); we now have a set of patient test scores for the COVIDpos 
patient sets, and one for the COVIDneg patient set. 
(2) Perform a two-sample t-test as well as a Mann-Whitney U test to get p-values against the 
null hypothesis that both sets have the same mean (for the t-test), and that both sets come 
from the same distribution (for the Mann-Whitney U test) 
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(3) Compute Cohen’s d (effect size) as a measure of the effect size of the difference; for the 
Mann-Whitney U test, the U statistic itself serves as an effect size. 
We then filtered by t-test p-value then ranked by Cohen’s d to identify which tests 
appeared to have the most differentiation between COVIDpos and COVIDneg scores; we then 
investigated some of these tests in deeper detail by looking at how they changed over time. We 
applied the same procedure to compute statistics for each of our time windows (restricting tests 
to the respective duration in each case). 
Augmented curation of anticoagulant administration and the coagulopathy outcomes from 
the unstructured clinical notes and their triangulation to structured EHR databases 
 A state-of-the-art BERT-based neural network8 was previously developed to classify 
sentiment regarding a diagnosis in the EHR21. Sentences containing phenotypes were classified 
into the following categories: Yes (confirmed diagnosis), No (ruled out diagnosis), Maybe 
(possibility of disease), and Other (alternate context, e.g. family history of disease). The neural 
network used to perform this classification was trained using nearly 250 different phenotypes and 
18,500 sentences and achieves 93.6% overall accuracy and over 95% precision and recall for 
Yes/No sentiment classification21. Here, this model was used to classify the sentiment around 
coagulopathies in the unstructured text of the 181 COVIDpos and 7,775 COVIDneg patients’ clinical 
notes, structuring this information so that it could be compiled with longitudinal lab measurement 
and medication information. 
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Table 1. Summary of patient characteristics for the overall COVIDpos, COVIDneg (matched), 
and COVIDneg cohorts.  The COVIDneg (matched) cohort was constructed using 1:10 propensity 
score matching to balance each of the clinical covariates, including: demographics (age, gender, 
race), medication use (anticoagulant/antiplatelet use within 30 days/1 year of PCR testing date), 
and hospitalization status on the date of PCR testing.   
Patient Characteristics COVIDpos COVIDneg (matched) COVIDneg 
Number of patients 181 1810 7775 
Age in years 59.9 59.7 63.9 
Gender 
Male 96 (53.0%) 956 (52.8%) 4064 (52.3%) 
Race: 
White 
Black 
Asian 
American Indian 
Other 
 
129 (71.3%) 
12 (6.6%) 
9 (5.0%) 
11 (6.1%) 
20 (11.0%) 
 
1329 (73.4%) 
149 (8.2%) 
95 (5.2%) 
48 (2.7%) 
189 (10.4%) 
 
6907 (88.8%) 
362 (4.7%) 
140 (1.8%) 
48 (0.6%) 
318 (4.1%) 
Medication use in the preceding 30 
days of PCR testing date: 
Anticoagulants 
Antiplatelets 
 
Medication use in the preceding 1 year 
of PCR testing date: 
Anticoagulants 
Antiplatelets 
 
29 (16.0%) 
24 (13.3%) 
 
 
 
35 (19.3%) 
35 (19.3%) 
265 (14.6%) 
249 (13.8%) 
 
 
 
377 (20.8%) 
360 (19.9%) 
 
 
2466 (31.7%) 
1498 (19.3%) 
 
 
 
3404 (43.8%) 
2461 (31.7%) 
Hospitalized on PCR testing date 23 (12.7%) 229 (12.7%) 1435 (18.5%) 
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Table 2. Summary of lab tests significantly different between COVIDpos and propensity 
score matched COVIDneg cohorts during at least one clinical time window. Data from 
individual patients was averaged over the defined time windows, and mean values were 
compared between COVIDpos and COVIDneg patients. The lab test-time window pairs shown are 
those with at least three patients contributing data in both cohorts which met our defined 
thresholds for statistical significance (cohen’s D > 0.35 and BH-adjusted Mann Whitney p-value 
< 0.05). Rows are sorted by the relative time window (from earliest to latest), and then by the 
adjusted Mann-Whitney p-value. Sample sources are denoted as: P = Plasma, S = Serum, S/P = 
Serum/Plasma, B = Blood, U = Urine. 
Test Units Time Window 
Count 
COVIDpos 
Count 
COVIDneg 
Mean 
COVIDpos 
Mean 
COVIDneg 
Cohen’s 
D 
Mann 
Whit U 
BH-adj MW 
p-value 
EOSINOPHILS 
ABSOLUTE x10(9)/L Pre-diagnosis 11 311 0.0531 0.173 -0.502 0.24 0.016 
EOSINOPHILS 
ABSOLUTE x10(9)/L 
Clinical 
presentation 54 607 0.0427 0.152 -0.499 0.22 2.8767E-09 
CALCIUM, TOTAL, S mg/dL 
Clinical 
presentation 46 541 8.22 8.93 -0.991 0.21 5.3938E-09 
BASOPHILS ABSOLUTE x10(9)/L 
Clinical 
presentation 50 498 0.0185 0.0379 -0.656 0.27 3.6512E-06 
RBC (RED BLOOD 
CELL) COUNT x10(12)/L 
Clinical 
presentation 87 1040 4.31 3.87 0.534 0.35 5.9047E-05 
HEMATOCRIT, B % 
Clinical 
presentation 87 1049 38.1 34.9 0.473 0.37 0.0005 
ALBUMIN, S/P g/dL 
Clinical 
presentation 38 378 3.26 3.75 -0.733 0.3 0.001 
CALCIUM, TOTAL, P mg/dL 
Clinical 
presentation 41 481 8.64 8.97 -0.535 0.32 0.001 
RED CELL 
DISTRIBUTION WIDTH 
CV % 
Clinical 
presentation 70 863 14.1 15 -0.427 0.36 0.001 
NEUTROPHILS, B x10(9)/L 
Clinical 
presentation 68 711 5.21 7.13 -0.371 0.37 0.003 
HEMOGLOBIN, B g/dL 
Clinical 
presentation 88 963 12.4 11.5 0.378 0.39 0.005 
LACTATE 
DEHYDROGENASE, S U/L 
Clinical 
presentation 19 81 467.2 340.5 0.456 0.25 0.006 
SODIUM, S mmol/L 
Clinical 
presentation 46 559 137 138.7 -0.437 0.36 0.009 
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MEAN CORPUSCULAR 
VOLUME fL 
Clinical 
presentation 87 1040 89.1 92 -0.386 0.4 0.011 
CARBOXYHEMOGLOBI
N, ARTERIAL % 
Clinical 
presentation 16 137 0.478 0.93 -0.705 0.27 0.016 
FIBRINOGEN, P mg/dL 
Clinical 
presentation 10 40 520 329.8 1.092 0.19 0.016 
TROPONIN T, 5TH GEN, 
P ng/L 
Clinical 
presentation 12 27 75.7 581.2 -0.58 0.21 0.019 
MAGNESIUM, PLASMA mg/dL 
Clinical 
presentation 12 130 2.11 1.9 0.704 0.27 0.041 
BICARBONATE, P mmol/L 
Clinical 
presentation 41 482 22.4 23.8 -0.35 0.38 0.044 
EOSINOPHILS 
PERCENT % 
Clinical 
presentation 7 63 0.3 1.4 -0.799 0.21 0.05 
MONOCYTES 
ABSOLUTE x10(9)/L 
Days 1-3 Post-
Dx 77 708 0.433 0.733 -0.581 0.27 2.8767E-09 
RBC (RED BLOOD 
CELL) COUNT x10(12)/L 
Days 1-3 Post-
Dx 98 1019 4.12 3.62 0.678 0.31 3.6246E-08 
HEMATOCRIT, B % 
Days 1-3 Post-
Dx 98 1016 36.3 32.7 0.591 0.33 2.6849E-06 
CALCIUM, TOTAL, S mg/dL 
Days 1-3 Post-
Dx 55 587 8.26 8.75 -0.787 0.28 3.6512E-06 
WHITE BLOOD CELLS x10(9)/L 
Days 1-3 Post-
Dx 98 980 6.82 9.01 -0.367 0.34 4.8081E-06 
EOSINOPHILS 
ABSOLUTE x10(9)/L 
Days 1-3 Post-
Dx 57 548 0.0815 0.182 -0.41 0.31 5.0765E-05 
ALKALINE 
PHOSPHATASE, S U/L 
Days 1-3 Post-
Dx 40 371 78.2 149.9 -0.394 0.29 0.0002 
HEMOGLOBIN, B g/dL 
Days 1-3 Post-
Dx 98 993 11.8 10.9 0.461 0.37 0.0003 
MEAN CORPUSCULAR 
VOLUME fL 
Days 1-3 Post-
Dx 98 1019 88.6 92 -0.459 0.37 0.0004 
BASOPHILS ABSOLUTE x10(9)/L 
Days 1-3 Post-
Dx 49 455 0.0188 0.0352 -0.57 0.32 0.001 
RED CELL 
DISTRIBUTION WIDTH 
CV % 
Days 1-3 Post-
Dx 78 829 14.2 15.1 -0.407 0.36 0.001 
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ALBUMIN, S/P g/dL 
Days 1-3 Post-
Dx 40 367 3.24 3.59 -0.623 0.31 0.001 
CALCIUM, TOTAL, P mg/dL 
Days 1-3 Post-
Dx 46 427 8.46 8.78 -0.533 0.33 0.002 
CALCIUM, IONIZED, B mg/dL 
Days 1-3 Post-
Dx 10 110 4.34 4.72 -0.941 0.15 0.003 
ALKALINE 
PHOSPHATASE, P U/L 
Days 1-3 Post-
Dx 25 220 82.8 114.7 -0.43 0.3 0.007 
MAGNESIUM, S/P mg/dL 
Days 1-3 Post-
Dx 17 161 2.45 1.93 1.24 0.26 0.008 
CARBOXYHEMOGLOBI
N, ARTERIAL % 
Days 1-3 Post-
Dx 22 160 0.536 0.864 -0.638 0.29 0.009 
TROPONIN T, 5TH GEN, 
P ng/L 
Days 1-3 Post-
Dx 12 23 130.1 741.4 -0.622 0.18 0.013 
OXYGEN SATURATION 
(%) IN ARTERIAL 
BLOOD % 
Days 1-3 Post-
Dx 15 102 94.8 96 -0.663 0.27 0.023 
LACTATE, P mmol/L 
Days 1-3 Post-
Dx 14 79 1.51 2.49 -0.495 0.28 0.042 
SODIUM, P mmol/L 
Days 1-3 Post-
Dx 46 438 136.6 138.1 -0.363 0.39 0.049 
RBC (RED BLOOD 
CELL) COUNT x10(12)/L 
Days 4-6 Post-
Dx 89 544 4.07 3.44 0.883 0.26 1.6397E-10 
HEMATOCRIT, B % 
Days 4-6 Post-
Dx 89 543 35.9 31.5 0.751 0.3 4.315E-08 
HEMOGLOBIN, B g/dL 
Days 4-6 Post-
Dx 89 518 11.7 10.2 0.743 0.3 1.0849E-07 
RED CELL 
DISTRIBUTION WIDTH 
CV % 
Days 4-6 Post-
Dx 75 444 14.1 15.6 -0.583 0.31 3.5305E-06 
MONOCYTES 
ABSOLUTE x10(9)/L 
Days 4-6 Post-
Dx 73 376 0.445 0.711 -0.594 0.31 1.2406E-05 
MEAN CORPUSCULAR 
VOLUME fL 
Days 4-6 Post-
Dx 89 544 88.7 92.6 -0.545 0.34 5.9047E-05 
MAGNESIUM, S/P mg/dL 
Days 4-6 Post-
Dx 23 131 2.34 1.93 1.177 0.23 0.0005 
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ALKALINE 
PHOSPHATASE, S U/L 
Days 4-6 Post-
Dx 35 229 86.9 153 -0.398 0.29 0.001 
EOSINOPHILS 
ABSOLUTE x10(9)/L 
Days 4-6 Post-
Dx 50 299 0.0917 0.205 -0.512 0.33 0.001 
CALCIUM, TOTAL, S mg/dL 
Days 4-6 Post-
Dx 49 352 8.33 8.7 -0.589 0.34 0.003 
MAGNESIUM, PLASMA mg/dL 
Days 4-6 Post-
Dx 16 114 2.19 1.96 0.859 0.24 0.005 
RABG CALCULATED O2 
HEMOGLOBIN % 
Days 4-6 Post-
Dx 9 20 92.8 95.8 -1.888 0.11 0.007 
CALCIUM, TOTAL, P mg/dL 
Days 4-6 Post-
Dx 43 235 8.54 8.9 -0.548 0.34 0.007 
BILIRUBIN, TOTAL, P mg/dL 
Days 4-6 Post-
Dx 17 118 0.429 1.36 -0.508 0.26 0.01 
CARBOXYHEMOGLOBI
N, ARTERIAL % 
Days 4-6 Post-
Dx 20 112 0.603 1.01 -0.645 0.3 0.019 
OXYGEN SATURATION 
(%) IN ARTERIAL 
BLOOD % 
Days 4-6 Post-
Dx 14 69 93.9 95.7 -0.867 0.27 0.029 
BICARBONATE, P mmol/L 
Days 4-6 Post-
Dx 43 228 23.8 25.5 -0.449 0.37 0.036 
RBC (RED BLOOD 
CELL) COUNT x10(12)/L 
Days 7-9 Post-
Dx 68 388 4.02 3.44 0.776 0.29 2.4811E-06 
MAGNESIUM, S/P mg/dL 
Days 7-9 Post-
Dx 20 97 2.35 1.89 1.457 0.17 0.00007767 
ALBUMIN, P g/dL 
Days 7-9 Post-
Dx 21 122 2.94 3.35 -0.666 0.28 0.007 
MONOCYTES 
ABSOLUTE x10(9)/L 
Days 7-9 Post-
Dx 52 288 0.472 0.686 -0.462 0.37 0.014 
CALCIUM, TOTAL, S mg/dL 
Days 7-9 Post-
Dx 41 261 8.48 8.8 -0.458 0.36 0.02 
ALBUMIN, S/P g/dL 
Days 7-9 Post-
Dx 39 197 3.36 3.63 -0.441 0.36 0.021 
TACROLIMUS, B ng/mL 
Days 7-9 Post-
Dx 5 45 4.54 7.9 -1.176 0.11 0.024 
CARBOXYHEMOGLOBI
N, ARTERIAL % 
Days 7-9 Post-
Dx 18 75 0.662 1.04 -0.593 0.3 0.037 
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RBC (RED BLOOD 
CELL) COUNT x10(12)/L 
Days 10-12 
Post-Dx 54 293 3.88 3.4 0.655 0.32 0.0003 
MAGNESIUM, S/P mg/dL 
Days 10-12 
Post-Dx 17 66 2.24 1.86 1.288 0.2 0.001 
MEAN CORPUSCULAR 
VOLUME fL 
Days 10-12 
Post-Dx 54 293 89.2 92.9 -0.514 0.34 0.001 
HEMATOCRIT, B % 
Days 10-12 
Post-Dx 54 288 34.4 31.2 0.528 0.35 0.003 
ALKALINE 
PHOSPHATASE, S U/L 
Days 10-12 
Post-Dx 31 153 102.2 182.6 -0.38 0.31 0.008 
PLATELETS x10(9)/L 
Days 10-12 
Post-Dx 54 270 298.7 243.4 0.361 0.36 0.008 
MAGNESIUM, PLASMA mg/dL 
Days 10-12 
Post-Dx 9 62 2.2 1.87 1.283 0.17 0.009 
LACTATE 
DEHYDROGENASE, S U/L 
Days 10-12 
Post-Dx 10 62 434.1 323.4 0.383 0.2 0.015 
HEMOGLOBIN, B g/dL 
Days 10-12 
Post-Dx 54 293 11.1 10.2 0.415 0.38 0.02 
TRIGLYCERIDES, S/P mg/dL 
Days 10-12 
Post-Dx 7 12 541.9 245.2 1.706 0.13 0.042 
MAGNESIUM, S/P mg/dL 
Days 13-15 
Post-Dx 14 52 2.21 1.79 1.566 0.13 0.0004 
BUN, P mg/dL 
Days 13-15 
Post-Dx 12 96 49 24.1 1.454 0.23 0.013 
MEAN CORPUSCULAR 
VOLUME fL 
Days 13-15 
Post-Dx 34 266 90.3 93.9 -0.511 0.34 0.016 
GLUPS GLUCOSE, P mg/dL 
Days 13-15 
Post-Dx 12 104 169.3 130.7 0.651 0.27 0.045 
BUN, P mg/dL 
Days 16-30 
Post-Dx 14 167 48.7 24.4 1.225 0.2 0.002 
MAGNESIUM, S/P mg/dL 
Days 16-30 
Post-Dx 10 93 2.21 1.83 1.223 0.19 0.009 
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Table 3. Prevalence of thrombotic phenotypes in COVIDpos patients with and without 
available longitudinal lab testing data. For each clotting phenotype listed, a BERT-based 
neural network was used to extract diagnostic sentiment from individual EHR patient notes in 
which the phenotype (or a synonym thereof) was present. In bold: absolute number of patients 
with each phenotype; in parentheses: percentage of thrombotic patients in each cohort (i.e., 
column) with the given specific thrombotic phenotype; in brackets: percentage of all patients in 
each cohort with the given specific thrombotic phenotype.  
Clotting Phenotype Cohort 1: COVIDpos with 
longitudinal data 
Cohort 2: COVIDpos without 
longitudinal data 
Cohort 3: Complete 
COVIDpos cohort 
Deep vein thrombosis 25 (76%) [14%] 2 (29%) [0.13%] 27 (68%) [1.6%] 
Pulmonary embolism 8 (24%) [4.4%] 3 (43%) [0.19%] 11 (28%) [0.64%] 
Myocardial infarction 3 (9%) [1.7%] 2 (29%) [0.13%] 5 (13%) [0.29%] 
Venous 
thromboembolism 
1 (3%) [0.55%] 0  1 (2.5%) [0.06%] 
Thrombotic stroke 2 (6%) [1.1%] 0 2 (5%) [0.12%] 
Cerebral venous 
thrombosis 
0 0 0 
Disseminated 
intravascular 
coagulation 
2 (6%) [1.1%] 0 2 (5%)[0.12%] 
Total Unique 
Patients with Clot 
33 [18%] 7 [0.84%] 40 [2.3%] 
Total Patients 181 1548 1729 
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Table 4. Enrichment of thrombotic phenotypes among COVIDpos patients with longitudinal 
lab testing data. Contingency table to calculate hypergeometric enrichment significance of 
thrombosis among patients with longitudinal lab testing data. The 181 patients with longitudinal 
testing data are those considered in this study, while the 1548 patients who did not have at least 
three results from one lab test over the defined 60-day window were excluded from this 
longitudinal analysis. 
 Patient has 
longitudinal data 
Patient does NOT have 
longitudinal data 
 
Thrombosis 33 7 40 
No Thrombosis 148 1541 1689 
 181 1548 1729 
 
Hypergeometric enrichment: p-value < 1 x 10-20 
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